search
Back to results

MVA85A Aerosol vs Intramuscular Vaccination in Adults With Latent Mycobacterium Tuberculosis (M. tb) Infection

Primary Purpose

Tuberculosis

Status
Terminated
Phase
Phase 1
Locations
United Kingdom
Study Type
Interventional
Intervention
Aerosol inhaled MVA85A
Intramuscular MVA85A
Intramuscular Saline placebo
Aerosol inhaled Saline placebo
Sponsored by
University of Oxford
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Tuberculosis focused on measuring MVA85A, Tuberculosis, Vaccine, Aerosol

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

Volunteers must meet all of the following criteria to enter the trial:

  • Healthy adult aged 18-55 years
  • Resident in or near Oxford, Birmingham or London for the duration of the trial period
  • Screening IGRA positive
  • Ineligible for chemoprophylaxis for latent M.tb infection, declined prophylaxis or considered low risk due to distant contact history
  • Chest Computed Tomography (CT) normal; or abnormal with features consistent with primary M.tb infection but no features suggestive of active disease
  • No relevant findings in medical history or on physical examination
  • Allow the Investigators to discuss the individual's medical history with their General Practitioner
  • Use effective contraception for the duration of the trial period (females only)
  • Refrain from blood donation during the trial
  • Give written informed consent
  • Allow the Investigator to register volunteer details with a confidential database (The Over-volunteering Protection Service) to prevent concurrent entry into clinical trials
  • Able and willing (in the Investigator's opinion) to comply with all the trial requirements

Exclusion Criteria:

Volunteers must meet none of the following criteria to enter the trial:

  • Participation in another research study involving receipt of an investigational product in the 30 days preceding enrolment, or planned use during the trial period
  • Prior vaccination with candidate vaccine MVA85A, candidate vaccine FP85A,any other recombinant MVA vaccine or any other candidate TB vaccine
  • Administration of immunoglobulins and/or any blood products within the three months preceding the planned trial vaccination date
  • Clinically significant history of skin disorder, allergy, atopy, immunodeficiency (including HIV), cancer (except BCC or CIS), cardiovascular disease, gastrointestinal disease, liver disease, renal disease, endocrine disorder, neurological illness, psychiatric disorder, drug or alcohol abuse
  • Concurrent oral or systemic steroid medication or the concurrent use of other immunosuppressive agents
  • History of anaphylaxis to vaccination or any allergy likely to be exacerbated by any component of the trial vaccine, sedative drugs, or any local or general anaesthetic agents
  • Pregnancy, lactation or intention to become pregnant during trial period
  • Any respiratory disease, including asthma
  • Current smoker
  • Clinically significant abnormality on screening CT thorax
  • Clinically significant abnormality of pulmonary function tests
  • Any nasal, pharyngeal, or laryngeal finding which precludes bronchoscopy
  • Current use of any medication taken through the nasal or inhaled route including cocaine or other recreational drugs
  • Clinical, radiological, or laboratory evidence of current active TB disease
  • Past treatment for TB disease
  • Any clinically significant abnormality of screening blood or urine tests
  • Positive HBsAg, HCV or HIV antibodies
  • Any other significant disease, disorder, or finding, which, in the opinion of the Investigator, may either put the volunteer at risk, affect the volunteer's ability to participate in the trial or impair interpretation of the trial data

Sites / Locations

  • Centre for Clinical Vaccinology and Tropical Medicine (CCVTM), Churchill Hospital
  • John Warin Ward, Churchill Hospital
  • NIHR Wellcome Trust Clinical Research Facility, University of Birmingham
  • NIHR/Wellcome Trust King's Clinical Research Facility
  • Royal Free Hospital NHS Foundation Trust

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

Starter Group

Group A

Group B

Arm Description

Receive 1x10^7 pfu aerosol inhaled MVA85A at day 0.

Receive 5x10^7 pfu aerosol inhaled MVA85A, and intramuscular saline placebo both at day 0.

Receive 5x10^7 pfu intramuscular MVA85A, and aerosol inhaled saline placebo both at day 0.

Outcomes

Primary Outcome Measures

Adverse Events (AE)
Actively and passively collected data on adverse events via diary card for 14 days after vaccination and at each visit over 6 months.

Secondary Outcome Measures

Laboratory Markers of Immunity
Evaluation of ex-vivo ELISpot and intracellular cytokine staining in blood and bronchoalveolar lavage (BAL) samples.

Full Information

First Posted
August 18, 2015
Last Updated
August 14, 2020
Sponsor
University of Oxford
Collaborators
University of Birmingham
search

1. Study Identification

Unique Protocol Identification Number
NCT02532036
Brief Title
MVA85A Aerosol vs Intramuscular Vaccination in Adults With Latent Mycobacterium Tuberculosis (M. tb) Infection
Official Title
A Phase I Trial to Compare the Safety and Immunogenicity of Candidate TB Vaccine MVA85A Administered by the Aerosol Inhaled Route and the Intramuscular Route in Healthy Adult Volunteers Who Are Latently Infected With Mycobacterium Tuberculosis
Study Type
Interventional

2. Study Status

Record Verification Date
November 2018
Overall Recruitment Status
Terminated
Why Stopped
Poor recruitment
Study Start Date
September 2015 (undefined)
Primary Completion Date
October 4, 2018 (Actual)
Study Completion Date
October 4, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Oxford
Collaborators
University of Birmingham

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
TB040 is a clinical trial to investigate and compare the effects of a candidate Tuberculosis (TB) vaccine, MVA85A, administered by the aerosol inhaled route and the intramuscular route in healthy adult volunteers who are latently infected with Mycobacterium tuberculosis.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Tuberculosis
Keywords
MVA85A, Tuberculosis, Vaccine, Aerosol

7. Study Design

Primary Purpose
Other
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
2 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Starter Group
Arm Type
Experimental
Arm Description
Receive 1x10^7 pfu aerosol inhaled MVA85A at day 0.
Arm Title
Group A
Arm Type
Experimental
Arm Description
Receive 5x10^7 pfu aerosol inhaled MVA85A, and intramuscular saline placebo both at day 0.
Arm Title
Group B
Arm Type
Experimental
Arm Description
Receive 5x10^7 pfu intramuscular MVA85A, and aerosol inhaled saline placebo both at day 0.
Intervention Type
Biological
Intervention Name(s)
Aerosol inhaled MVA85A
Other Intervention Name(s)
MVA85A
Intervention Type
Biological
Intervention Name(s)
Intramuscular MVA85A
Other Intervention Name(s)
MVA85A
Intervention Type
Biological
Intervention Name(s)
Intramuscular Saline placebo
Other Intervention Name(s)
Saline
Intervention Type
Biological
Intervention Name(s)
Aerosol inhaled Saline placebo
Other Intervention Name(s)
Saline
Primary Outcome Measure Information:
Title
Adverse Events (AE)
Description
Actively and passively collected data on adverse events via diary card for 14 days after vaccination and at each visit over 6 months.
Time Frame
Up to Day 168
Secondary Outcome Measure Information:
Title
Laboratory Markers of Immunity
Description
Evaluation of ex-vivo ELISpot and intracellular cytokine staining in blood and bronchoalveolar lavage (BAL) samples.
Time Frame
Up to Day 168

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Volunteers must meet all of the following criteria to enter the trial: Healthy adult aged 18-55 years Resident in or near Oxford, Birmingham or London for the duration of the trial period Screening IGRA positive Ineligible for chemoprophylaxis for latent M.tb infection, declined prophylaxis or considered low risk due to distant contact history Chest Computed Tomography (CT) normal; or abnormal with features consistent with primary M.tb infection but no features suggestive of active disease No relevant findings in medical history or on physical examination Allow the Investigators to discuss the individual's medical history with their General Practitioner Use effective contraception for the duration of the trial period (females only) Refrain from blood donation during the trial Give written informed consent Allow the Investigator to register volunteer details with a confidential database (The Over-volunteering Protection Service) to prevent concurrent entry into clinical trials Able and willing (in the Investigator's opinion) to comply with all the trial requirements Exclusion Criteria: Volunteers must meet none of the following criteria to enter the trial: Participation in another research study involving receipt of an investigational product in the 30 days preceding enrolment, or planned use during the trial period Prior vaccination with candidate vaccine MVA85A, candidate vaccine FP85A,any other recombinant MVA vaccine or any other candidate TB vaccine Administration of immunoglobulins and/or any blood products within the three months preceding the planned trial vaccination date Clinically significant history of skin disorder, allergy, atopy, immunodeficiency (including HIV), cancer (except BCC or CIS), cardiovascular disease, gastrointestinal disease, liver disease, renal disease, endocrine disorder, neurological illness, psychiatric disorder, drug or alcohol abuse Concurrent oral or systemic steroid medication or the concurrent use of other immunosuppressive agents History of anaphylaxis to vaccination or any allergy likely to be exacerbated by any component of the trial vaccine, sedative drugs, or any local or general anaesthetic agents Pregnancy, lactation or intention to become pregnant during trial period Any respiratory disease, including asthma Current smoker Clinically significant abnormality on screening CT thorax Clinically significant abnormality of pulmonary function tests Any nasal, pharyngeal, or laryngeal finding which precludes bronchoscopy Current use of any medication taken through the nasal or inhaled route including cocaine or other recreational drugs Clinical, radiological, or laboratory evidence of current active TB disease Past treatment for TB disease Any clinically significant abnormality of screening blood or urine tests Positive HBsAg, HCV or HIV antibodies Any other significant disease, disorder, or finding, which, in the opinion of the Investigator, may either put the volunteer at risk, affect the volunteer's ability to participate in the trial or impair interpretation of the trial data
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Helen McShane
Organizational Affiliation
University of Oxford
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Paul Moss
Organizational Affiliation
University of Birmingham
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Marc Lipman
Organizational Affiliation
Royal Free Hostpital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Felicity Perrin
Organizational Affiliation
King's College Hospital NHS Trust
Official's Role
Principal Investigator
Facility Information:
Facility Name
Centre for Clinical Vaccinology and Tropical Medicine (CCVTM), Churchill Hospital
City
Oxford
State/Province
Oxfordshire
ZIP/Postal Code
OX3 7LE
Country
United Kingdom
Facility Name
John Warin Ward, Churchill Hospital
City
Oxford
State/Province
Oxfordshire
ZIP/Postal Code
OX3 7LE
Country
United Kingdom
Facility Name
NIHR Wellcome Trust Clinical Research Facility, University of Birmingham
City
Birmingham
State/Province
West Midlands
ZIP/Postal Code
B15 2TH
Country
United Kingdom
Facility Name
NIHR/Wellcome Trust King's Clinical Research Facility
City
London
Country
United Kingdom
Facility Name
Royal Free Hospital NHS Foundation Trust
City
London
Country
United Kingdom

12. IPD Sharing Statement

Learn more about this trial

MVA85A Aerosol vs Intramuscular Vaccination in Adults With Latent Mycobacterium Tuberculosis (M. tb) Infection

We'll reach out to this number within 24 hrs